文献速递糖尿病

二肽基肽酶4抑制剂与二甲双胍对新发痴呆的比较:一项倾向性评分匹配队列研究

Dipeptidyl Peptidase 4 Inhibitors vs Metformin for New-onset Dementia: A Propensity Score-matched Cohort Study.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该研究基于中国肾脏疾病数据系统2009至2020年数据,纳入40岁以上新使用二肽基肽酶4(DPP4)抑制剂或二甲双胍的2型糖尿病患者,经1:1倾向性评分匹配后每组3626例。调整混杂因素后,与二甲双胍相比,使用DPP4抑制剂与全因痴呆风险降低相关(HR 0.63,95%CI 0.45-0.89),在60岁及以上起始治疗者及无基线大血管或微血管并发症者中同样观察到关联。

要点

  • 与二甲双胍相比,DPP4抑制剂使用与全因痴呆风险降低相关(HR 0.63,95%CI 0.45-0.89)。
  • 60岁及以上起始药物治疗者中,DPP4抑制剂与痴呆风险降低相关(HR 0.69,95%CI 0.48-0.98)。
  • 无基线大血管并发症者HR 0.62(95%CI 0.41-0.96),无基线微血管并发症者HR 0.67(95%CI 0.47-0.98)。

核心结论

  • 在这项真实世界研究中,与二甲双胍相比,DPP4抑制剂在2型糖尿病患者中与较低的痴呆风险相关,尤其在老年人和无糖尿病相关合并症者中。

研究设计与样本

  • 基于中国肾脏疾病数据系统2009至2020年数据的倾向性评分匹配队列研究,纳入40岁以上新使用DPP4抑制剂或二甲双胍的2型糖尿病患者,经1:1倾向性评分匹配后每组各3626例。

主要发现

  • 经1:1倾向性评分匹配后,分析纳入3626例DPP4抑制剂新用户和同等数量的二甲双胍新用户。
  • 调整潜在混杂因素后,与二甲双胍相比,使用DPP4抑制剂与全因痴呆风险降低相关(HR 0.63,95%CI 0.45-0.89)。
  • 亚组分析显示,在60岁及以上起始药物治疗者中,使用DPP4抑制剂与痴呆发生率降低相关(HR 0.69,95%CI 0.48-0.98)。
  • 无基线大血管并发症者中,使用DPP4抑制剂与痴呆风险降低相关(HR 0.62,95%CI 0.41-0.96)。
  • 无基线微血管并发症者中,使用DPP4抑制剂与痴呆风险降低相关(HR 0.67,95%CI 0.47-0.98)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypoglycemic pharmacotherapy interventions for alleviating the risk of dementia remain controversial, particularly regarding dipeptidyl peptidase 4 (DPP4) inhibitors vs metformin. Our objective was to investigate whether the initiation of DPP4 inhibitors, as opposed to metformin, was linked to a reduced risk of dementia. METHODS: We included individuals with type 2 diabetes over 40 years old who were new users of DPP4 inhibitors or metformin in the Chinese Renal Disease Data System database between 2009 and 2020. The study employed Kaplan-Meier and Cox regression for survival analysis and the Fine and Gray model for the competing risk of death. RESULTS: Following a 1:1 propensity score matching, the analysis included 3626 DPP4 inhibitor new users and an equal number of metformin new users. After adjusting for potential confounders, the utilization of DPP4 inhibitors was associated with a decreased risk of all-cause dementia compared to metformin [hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.45-0.89]. Subgroup analysis revealed that the utilization of DPP4 inhibitors was associated with a reduced incidence of dementia in individuals who initiated drug therapy at the age of 60 years or older (HR 0.69, 95% CI 0.48-0.98), those without baseline macrovascular complications (HR 0.62, 95% CI 0.41-0.96), and those without baseline microvascular complications (HR 0.67, 95% CI 0.47-0.98). CONCLUSION: In this real-world study, we found that DPP4 inhibitors presented an association with a lower risk of dementia in individuals with type 2 diabetes than metformin, particularly in older people and those without diabetes-related comorbidities.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Liu S, Wan H, Nie S, et al. Dipeptidyl Peptidase 4 Inhibitors vs Metformin for New-onset Dementia: A Propensity Score-matched Cohort Study. J Clin Endocrinol Metab. 2025. PMID: 38652239. doi:10.1210/clinem/dgae281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。